Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

GlobeNewswire 10 days ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

GlobeNewswire October 8, 2024

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

GlobeNewswire September 30, 2024

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

GlobeNewswire September 20, 2024

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

GlobeNewswire September 17, 2024

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

GlobeNewswire August 15, 2024

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

GlobeNewswire August 14, 2024

Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate

GlobeNewswire May 23, 2024

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 16, 2024

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

GlobeNewswire May 7, 2024

Traws Pharma Announces New Employee Inducement Grants

GlobeNewswire April 2, 2024

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

GlobeNewswire April 2, 2024

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

GlobeNewswire March 8, 2024

Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

GlobeNewswire December 12, 2023

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

GlobeNewswire December 8, 2023

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

GlobeNewswire November 28, 2023

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

GlobeNewswire November 14, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire November 7, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

GlobeNewswire November 2, 2023

Onconova Expands Leadership Team with Two Key Appointments

GlobeNewswire October 24, 2023